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Background: Depot antipsychotic injections are an important tool for the management of patients with
schizophrenia who have difficulty with adherence to oral medication. However, pain and discomfort at the injection
site can be a potential impediment to the use of these long-acting formulations. We report here the results of a
pooled analysis of injection site-related adverse events (AEs) collected during treatment with the olanzapine long-
acting injection (olanzapine LAI).
Methods: Unsolicited injection site-related AEs were pooled from 7 olanzapine LAI clinical trials conducted in
patients between March 2001 and December 2010. All patients had a Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition (DSM-IV) or Fourth Edition, Text Revision (DSM-IV-TR) diagnosis of schizophrenia or
schizoaffective disorder and were between the ages of 18 and 75. Doses ranged from 45 to 405 mg olanzapine LAI,
and injection intervals were 2, 3, or 4 weeks. Events were evaluated for severity, timing, possible risk factors, and
outcome. A criterion of p < .05 for statistical significance was used for all tests.
Results: A total of 1752 patients received at least 1 olanzapine LAI injection. Of these, 92 patients (5.3%) reported at
least 1 injection site-related AE, with “pain” being the most common type (2.9%). Most events were mild (81.4%)
and the median duration was 3 days. Four patients (0.2%) discontinued due to injection site-related AEs. Dose
volume and body mass index did not appear to affect the probability of injection site-related AEs. However, patients
who experienced a post-injection delirium/sedation syndrome event (n = 37) were more likely to have or have had
an injection site-related AE at some time during the study. Incidence of injection site-related AEs appeared to
decrease over time. In 94.2% of the injection site-related AEs, no specific treatment or concomitant medication was
reported; in 9 cases, patients received pharmacologic treatment for reaction, mass, abscess, rash, or pain.
Conclusions: Injection site-related AEs with olanzapine LAI were generally mild. The incidence and nature of these
injection site-related AEs were generally similar to those occurring during treatment with other injectable antipsychotics.
Trial registration: ClinicalTrials.gov ID; URL: NCT00094640, NCT00088478, NCT00088491, NCT00088465, and
NCT00320489.
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Despite advances in the treatment of schizophrenia with
the use of newer atypical antipsychotic agents, treatment
nonadherence continues to be a problematic and costly
issue. As many as one-third of outpatients are reported to
be completely noncompliant, and another third are re-
ported to be only partially compliant [1]. Moreover, patient
adherence has been found to worsen over time, with up to
75% of patients demonstrating only partial or worse com-
pliance after 2 years of treatment [2].
Long-acting depot injections of antipsychotic agents are
important in the treatment of schizophrenia because they
may help mitigate treatment noncompliance and its con-
sequences. However, pain and discomfort at the injection
site can be a potential impediment to the use of these
depot formulations. Injection site adverse events (AEs), in-
cluding injection site pain, have been reported with con-
ventional and atypical depot agents [3-6]. However, the
extent of injection site-related AEs reported with inject-
able long-acting antipsychotic medications is not widely
studied in the literature. Rates as low as 1.9% [7] and as
high as 10% [8] have been reported in different papers.
Olanzapine long-acting injection (LAI) is a depot an-
tipsychotic formulation consisting of a pamoate salt of
olanzapine that is administered by deep intramuscular in-
jection every 2 to 4 weeks [9]. The efficacy and safety of
olanzapine LAI have been established in the treatment of
schizophrenia in several reports [10-12]. In addition, the
efficacy and safety of olanzapine LAI have been shown to
be similar to that of oral olanzapine [10], with the excep-
tion being incidence of local injection site-related AEs and
post-injection delirium/sedation syndrome (PDSS) events.
PDSS events, characterized by signs of delirium and/or ex-
cessive sedation consistent with symptoms of olanzapine
overdose, were identified during clinical studies and oc-
curred in 0.07% of injections and in approximately 1.4% of
patients [13]. Because of the risk of PDSS, safety precau-
tions outlined in the approved label—including a post-
injection observation period—must occur at the time of
each injection [9].
The purpose of this paper is to determine the extent
and nature of injection site-related AEs in patients treated
with olanzapine LAI. An analysis of pooled data from 7
olanzapine LAI studies will be presented.
Methods
Studies
This pooled analysis is based on 7 olanzapine LAI clinical
trials that were conducted in patients between March
2001 and December 2010: a single-dose pharmacokinetic
study (N = 134, Study F1D-EW-LOBS), a 2-month phar-
macokinetic study (N = 9, Study F1D-EW-LOBO), a re-
ceptor occupancy study (N = 14, Study F1D-EW-HGJW)
[14], an 8-week randomized, placebo-controlled acuteefficacy study (olanzapine LAI N = 304, Study F1D-MC-
HGJZ) [11], a 24-week randomized, oral olanzapine-
controlled maintenance study (olanzapine LAI N = 743,
Study F1D-MC-HGKA) [10], a 2-year randomized, oral
olanzapine-controlled open-label efficacy study (olanzapine
LAI N = 264, Study F1D-MC-HGLQ), and a 6-year open-
label extension study (N = 931, Study F1D-MC-HGKB)
[12]. In addition there was 1 trial (Study F1D-EW-LOBE, a
6-month pharmacokinetic study) that was not included in
this analysis due to the fact that the injection-related AEs
for that study were collected through active solicitation
(27.8% of patients [N = 302] reporting an injection site-
related AE) and thus were not comparable with those of
the other studies, which relied solely upon spontaneous
reporting of AEs.
Subjects
All patients had a diagnosis of schizophrenia or schizoaf-
fective disorder, as defined by the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition (DSM-IV) or
Fourth Edition, Text Revision (DSM-IV-TR), were between
the ages of 18 and 75, and had at least 1 olanzapine LAI in-
jection [13]. Exclusion criteria included significant suicidal
or homicidal risk; pregnancy or breastfeeding; acute, ser-
ious, or unstable medical conditions; or substance depend-
ency (except nicotine or caffeine) within the past month.
Olanzapine LAI injection procedures
Patients received their injections after completion of all
efficacy and safety assessments at that visit. Injections
were generally administered into alternating sides of the
buttocks from visit to visit, and administrators were ad-
vised not to massage the injection area after injection.
Injections were administered using a 19-gauge 1.5-inch
(or 35-mm) needle; a 2-inch (or 50-mm) needle could
be used for obese patients. Doses ranged from 45 to
405 mg olanzapine LAI, and injection intervals could be
2, 3, or 4 weeks, depending on the specific study. Injec-
tions given at 2-week intervals could not exceed a dose
of 300 mg.
Statistical analyses
All analyses were performed using SAS version 9.1 (SAS
Institute, Inc., Cary, N.C.). Only injection site-related AEs
were assessed (i.e., AEs with Medical Dictionary for Regu-
latory Activities [MedDRA] preferred terms that contained
the phrase “injection site”). The Cochran-Armitage test for
trend was used to assess whether there was any increasing
or decreasing trend in the relationship between the pres-
ence of injection site-related AEs and injection volume
(specific doses were 45, 135, 150, 210, 225, 255, 270, 300,
330, 345, 360, 375, and 405 mg), or body mass index
(BMI; categories were underweight [BMI < 18.5]; normal
weight [BMI ≥18.5, <25]; overweight [BMI ≥25, <30]; and
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egory could change over the course of a study, BMI at the
first injection was used for patients who never reported an
injection site-related AE, but for patients with injection
site-related AEs BMI at the first occurrence was used. Chi-
square tests were used to compare any 2 proportions.
Fisher’s Exact test was used to compare the percentage of
patients experiencing both PDSS and at least one injection
site-related AEs with the percentage of patients who expe-
rienced PDSS only. A criterion of p < .05 for statistical sig-
nificance was used for all tests.
Results
From the 7 pooled studies, a total of 1752 patients re-
ceived at least 1 olanzapine LAI injection (Total = 56,240
injections). Of these 1752 patients, 92 (5.3%) reported at
least 1 injection site-related AE (Table 1). There was a
total of 156 injection site-related AEs. Table 1 also pre-
sents events that occurred more than once for patients.
Out of 92 patients who experienced an injection site-
related AE, 19 (20.7%) experienced the same event more
than once. Of the patients who experienced an injection
site-related AE, a substantial percentage (42.4%) experi-
enced pain only and no other type of event.
All injection site-related AEs were classified by the in-
vestigator as mild, moderate, or severe: 81.4% of the events
were considered mild, 17.3% were of moderate severity,
and 2 events (1.3%, both injection site reactions) wereTable 1 Percentages of patients with injection site-
related adverse events
Preferred term Patients with 1
or more event




Any injection site-related AE 92 (5.3) 19 (20.7)
Injection site pain 50 (2.9) 6 (12.0)
Injection site reaction 10 (0.6) 1 (10.0)
Injection site mass 8 (0.5) 3 (37.5)
Injection site swelling 8 (0.5) 3 (37.5)
Injection site induration 6 (0.3) 1 (16.7)
Injection site nodule 6 (0.3) 2 (33.3)
Injection site irritation 5 (0.3) 2 (40.0)
Injection site abscess 4 (0.2)
Injection site haemorrhage 4 (0.2) 1 (25.0)
Injection site warmth 3 (0.2)
Injection site erythema 2 (0.1)
Injection site discolouration 1 (0.1)
Injection site extravasation 1 (0.1)
Injection site oedema 1 (0.1)
Injection site paraesthesia 1 (0.1)
Injection site rash 1 (0.1) 1 (100.0)
Abbreviation: AE adverse event.severe. Four patients (0.2%) discontinued due to injection
site-related AEs (1 each of injection site reaction [severe],
nodule [moderate severity], swelling [moderate severity],
and a mass [mild severity]). None of these subjects had ex-
perienced a previous event.
There was no significant relationship between dose
volume and the probability of an injection site-related
AE (p = .149).
An analysis of injection site-related AEs and PDSS
events demonstrated that the percentage of patients who
experienced a PDSS event was greater among those who,
at some point during the study, also experienced an injec-
tion site-related AE versus those who did not (5/92 = 5.4%
vs. 32/1660 = 1.9%; Fisher’s Exact test p = .041).
We also tested if the percentage of patients experiencing
an injection site-related AE was associated with BMI. The
percentages of patients in each of the BMI categories
who experienced an injection site-related AE were as fol-
lows: underweight (6.1%); normal weight (4.5%); over-
weight (5.1%); and obese (6.3%). BMI category was not
significantly associated with percentage of injection site-
related AEs (Cochran-Armitage test for trend, p = .254).
The timing of injection site-related AEs over the course
of treatment is shown in Figure 1. The percentage of events
appears to decrease with successive injections.
The durations of injection site-related AEs are shown
in Table 2. It should be noted that 1 data point was ex-
cluded from the data analysis because it was an extreme
outlier and most likely an error (1097 days of injection
site pain, which was greater than 300 times the median).
The median duration of all occurrences of all event types
for which duration was known was 3 days. The largest
category of AE was injection site pain, which had a me-
dian duration of 1.5 days. Durations of 18 events are
missing because they were not recovered, were recover-
ing/resolving, or were unknown at the time the patient
discontinued the study.
Medications were provided when necessary for the treat-
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Figure 1 Timing of injection site-related adverse events, by
injection. Abbreviation: AE = adverse event.
Table 2 Duration of injection site-related adverse events (combined and separately for injection site pain)
N Mean SD Min. 25th Percentile Med. 75th Percentile Max.
All events
Duration of all occurrences, days 137 9.7 16.9 1 1 3 11 117
Duration of first occurrence, days 98 10.0 14.9 1 1 3 14 86
Injection site pain
Duration of all occurrences, days 68 3.6 5.0 1 1 1.5 3.5 32
Duration of first occurrence, days 48 4.4 5.7 1 1 2.5 4.5 32
Abbreviations: Max maximum, Med median, Min minimum, SD standard deviation.
Note: One data point was excluded because it was an extreme outlier. Durations are not known for 18 events.
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concomitant medications were administered (or at least
captured and tied specifically to the event). However, con-
comitant medications were given to 9 patients with injec-
tion site-related AEs. Cefalexin was given to 5 patients for
diverse events (2 patients with abscesses, 2 with injection
site reactions, and 1 with a mass), hydrocortisone was given
to 1 patient with a mass, amoxicillin was given to 1 patient
with an injection site reaction, sodium metamizole was
given to 1 patient for pain, and betamethasone was given
to 1 patient with a rash.
Discussion
The safety and efficacy of olanzapine LAI have been re-
ported previously and have been shown to be similar to
those of oral olanzapine [10-12], with the exception
being the occurrence of injection-related AEs. Injection-
related AEs for olanzapine LAI can include AEs local-
ized to the injection site itself but can also include PDSS
events [13,15]. The purpose of the present analysis was
to focus specifically on injection site-related AEs, which
are not well understood but may have an impact on
patient satisfaction and treatment adherence.
Injection site-related AEs occurred in a small percentage
of patients (5.3%). When these did occur, most were identi-
fied as mild (81.4%), with a median duration of 3 days. Pain
was the most common type of event, occurring in 2.9% of
patients, but each of the other types of injection site-related
AEs occurred in fewer than 1% of patients. Dose volume
and BMI did not appear to affect the probability of injection
site-related AEs. The percentage of patients who experi-
enced a PDSS event was greater among those who, at some
point during the study, also experienced an injection site-
related AE versus those who did not (5.4% vs. 1.9%,
p = .041). This may be related to unknown factors at the in-
jection site that may make these patients at higher risk for
both events and needs to be further explored. However, it
should be noted that this relationship is based on a small
number of patients with an event (n = 37) and that these
shared risk factors imply only an association between the
injection site-related AEs and PDSS and that these events
are not necessarily causally related.There was some evidence that the likelihood of an event
decreases with the number of injections received. This is
somewhat expected, however, as patients who are not sus-
ceptible to injection site events will tend to stay on the
medication longer. In addition, this trend could be en-
hanced by the decreased reporting of certain events, such
as pain or irritation, over time as the patient becomes ac-
climated to the injections.
The most common injection site-related AE was pain
(2.9% of patients). In a very few instances, the pain resulted
in the prescription of an analgesic. The other medications
prescribed were antibiotics or an anti-inflammatory, pre-
scribed for injection site reaction, mass, abscess, or rash.
There were very few discontinuations due to injection site-
related AEs.
The incidence of injection site-related AEs in the present
analysis was similar to that found in previous studies of in-
jectable neuroleptics. In a recent review of a small number
of olanzapine LAI studies, Cañas and Möller [16] noted an
injection site AE rate of 3.6%. Hamann et al. [4] found that
7.7% of subjects experienced an injection site reaction after
administration of haloperidol decanoate. Citrome [8] re-
cently reviewed 6 studies of paliperidone palmitate and
found rates of injection site reactions of 4% to 10%. Quiroz
et al. [7], reporting the results of 2 studies of risperidone
LAI, found the incidence of injection site-related AEs was
≤2% (Study 1, N = 170). In the second study (N = 53) injec-
tion site pain and injection site reaction were reported as
AEs by 7.5% and 1.9% of patients, respectively. Thus, the
5.3% incidence of injection site-related AEs observed with
olanzapine LAI appears within the same range as that ob-
served with other injectable antipsychotics, despite the use
of a larger needle size and a larger volume of medication
being injected with olanzapine LAI.
It is not possible to avoid all local injection site-related
AEs, but some may be prevented by proper injection
techniques [17,18]. Some important considerations include
having aseptic conditions and keeping patients relaxed
during injection (avoiding sudden movement). There is
also the potential that pain can be reduced by ensuring
that the medication is at room temperature at time of
injection, giving the injection using the right momentum
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quickly could contribute to a greater risk of ‘tearing’ of
muscle fibers resulting in trauma at site of injection), and
using comfort measures, such as the application of heat or
cold to the injection site [19]. Jones et al. [5] also found
that decreasing the size of injections (more concentrated)
and the frequency of injections reduced the rate of injec-
tion site-related AEs. Olanzapine LAI does not require re-
frigeration and should be injected with steady, continuous
pressure [9]. Although it is not recommended to massage
the site after the injection, use of a cold compress is an
acceptable comfort measure [19]. Olanzapine LAI is only
offered at 1 concentration; however, dosing and injection
frequency can be modified to decrease injection frequency
to monthly if needed. A needle smaller than 19 gauge
should not be used as this could increase the risk of
needle clogging [9].
Limitations
The authors recognize several limitations of this report and
the studies from which the data were drawn. First, although
the majority of the injection site-related AEs were injection
site pain, none of the studies included a formal assessment
of pain severity. Second, some patients reported injection
site-related AEs as ongoing at the time of discontinuation
from the study, and thus it is not possible to know the out-
come of these events. Finally, our event-term search strat-
egy required “injection site” to be specified in the event
term; however there may be other events in the database
which were related to the injection but were excluded be-
cause the location of the reaction was not specified.
Conclusions
For patients treated with olanzapine LAI, injection site-
related AEs were generally mild. Pain was the most com-
mon type of event, occurring in 2.9% of patients, but each
of the other types of injection site-related AEs occurred in
fewer than 1% of patients. The incidence and nature of
these injection site events were generally similar to those
occurring during treatment with other injectable antipsy-
chotics. Importantly, the rate of discontinuation due to in-
jection site-related AEs was low, suggesting that the risk
of these adverse events will not change the benefit/risk
profile for most patients considering treatment with depot
medications.
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